1652 — Fusen Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- HK$674.64m
- HK$1.01bn
- CNY565.61m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 407 | 487 | 386 | 492 | 566 |
Cost of Revenue | |||||
Gross Profit | 212 | 266 | 211 | 225 | 300 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 341 | 425 | 353 | 486 | 566 |
Operating Profit | 66.1 | 61.9 | 32.9 | 5.75 | -0.313 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 63.8 | 78.4 | 23.8 | -31 | -29.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 52.3 | 62.7 | 16.6 | -34.7 | -36.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 53.4 | 70.1 | 16.6 | -34.6 | -36.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 53.4 | 70.1 | 16.6 | -34.6 | -36.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.067 | 0.112 | 0.05 | -0.012 | -0.03 |
Dividends per Share |